• U.S.A
  • Europe
  • Japan
  • Message
  • Business Domain
  • Overview
  • Philosophy
  • Members of the Managing Board
  • History
  • Global Network
  • Plants
  • Creating Shared Value (CSV)
  • IR
  • Amino Acids
  • Peptides
  • Nucleic Acids
  • HMOs
  • Contact Us
  • Dipeptides



Kyowa Hakko Bio succeeded its bio-chemical business from Kyowa Hakko Kogyo and was established in 2008. Kyowa Hakko Kogyo can thus be regarded as the predecessor of Kyowa Hakko Bio.

Kyowa Hakko Kogyo

1949 Establishment of Kyowa Hakko Kogyo.
1951 Introduced production technology of Streptomycin, an anti-tubercular drug from US pharmaceutical company Merck & Co. Inc., and succeeded in its mass production.
1956 Succeeded in the isolation and commercial mass-production of the anticancer drug MitomycinC.
World's first invention of the process of L-Glutamic acid production by fermentation. Pioneered in the major business industry of amino-acid fermentation.
1958 Invention of the process of L-Lysine production by fermentation.
Release of a plant growth regulator Gibberellin Kyowa (contributed to production of seedless grapes).
1969 Establishment of Kyowa Hakko USA.
1973 Establishment of Kyowa Hakko Europe.
1981 Establishment of the Bio Business Headquarters.
2005 Completion of the transition to an operating holding company (Pharmaceuticals and Bio-chemicals are its main pillars).
2007 Announcement of a strategic alliance between Kyowa Hakko Group and Kirin Group.

Kyowa Hakko Bio

2008 Establishment of Kyowa Hakko Bio
(succeeded Bio-Chemical business from Kyowa Hakko Kogyo).
Announcement of a strategic alliance between Kyowa Hakko Group and Kirin Group.
2015 Completion of Construction for Amino Acid Manufacturing Plant in Thailand
2019 Became a direct subsidiary of Kirin Holdings
Company, Limited through transfer of shares